Randomized controlled trial of effects of metformin in NAFLD patients with newly diagnosed type 2 diabetes treated with an intensive lifestyle: a study protocol
Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM) are common chronic diseases. The coexistence of NAFLD and diabetes accelerates the progression of both and tends to induce bad prognosis. To date, lifestyle modification has been suggested as the first-line treatment for NAFLD patients. Some studies indicated that lifestyle modification could normalize glucose levels in newly diagnosed T2DM, but many individuals do not reach glycemic targets in practice using lifestyle modification alone. Considering the tight link between NAFLD and T2DM, metformin, a widely used drug in diabetic patients with a good safety profile, may be a possible treatment or control of NAFLD progression. There is no therapeutic consensus for the treatment of NAFLD patients with diabetes. Therefore, it is essential to elucidate the beneficial effects of lifestyle modification combined with metformin on glucose-lipid metabolism in the NAFLD population with newly diagnosed T2DM.
Methods: Participants will be recruited in this single-center, randomized clinical trial through telephone interview. All participants will be assigned randomly at a 1:1:1 ratio to three groups and treated with lifestyle modification including calorie-restricted dietary and exercise therapy, 500-2000 mg/day metformin, or treated with both lifestyle modification and 500-2000 mg/day metformin (the co-intervention group) for 12 weeks. The primary outcomes are changes in glycemic control and severity of…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.